Rome, June 4 (beraking latest news Salute) – In Italy so far there have been 5,861 Covid patients treated with monoclonal antibodies, and entered in the special monitoring register created by the Italian Medicines Agency (Aifa). Therefore, in almost 3 months – i.e. from 10 March, when these specific drugs were authorized as an emergency in Italy for particularly fragile people with recent Sars-CoV-2 infection and without severe symptoms, to 3 June, the date of update of the Aifa monitoring report, published today on the agency’s website – 192 structures from 21 Regions or Autonomous Provinces have prescribed these therapies.
Since the start of monitoring, in absolute numbers, Veneto is the Region with the greatest use with 773 patients treated, followed by Lazio (764) and Tuscany (712), while the Autonomous Province of Bolzano with 3 patients in the last places. entered in the register and Molise with 13. To date, most of the patients treated (3,315 out of a total of 5,861), have received the combination of the two antibodies bamlanivimab and etesevimab.
In particular, in the week from 28 May to 3 June – the subject of the report – 135 prescriptions were made, with an average of about 19 per day, down from the previous week when there were about 35 per day). Furthermore, compared to the resident population in the last week monitored, 2 doses were used for every million inhabitants in Italy, down from the 4 doses of the previous week.
COPYRIGHT today © breaking latest news